Tagged with CEE

Europe The EMA’s Pre-Accession Assistance Program (IPA) helps EU candidate and potential candidate countries align their medicines regulations with EU standards through training, capacity-building, and policy support. As a new op-ed in the February 2025 edition of DIA’s Global Forum magazine outlines, an impact assessment of IPA II (2020-2023) showed significant…

CEE A roundup of some of the top news coming out of the Central and Eastern European (CEE) region’s pharma industry, including Poland’s first draft of a national critical medicines list; Polpharma’s acquistion of the dermatological firm Ziołolek; Sopharma’s sale of its logistics unit, Farmalogistika; Horus Pharma’s significant stake in Romania’s…

CEE Some of the biggest stories coming out of the Central and Eastern European (CEE) region’s pharma industry, including the European Bank’s EUR 25 million investment in Pelion Group; the amendments to Poland’s drug reimbursement act; Pfizer’s legal proceedings against Hungary, Poland and Romania, and Egis Pharma’s expansion beyond Hungary.  …

Poland With a geostrategic location and easy access to both Western Europe and the rest of the emerging Central and Eastern Europe (CEE) region, Poland represents the sixth largest pharma market in the European Union. Having demonstrated steady year-on-year growth, the market, with its strong generics-centred local players, is set to…

CEE Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Polpharma’s bid for Zentiva, Richter’s acquisition of OC Distributors and MDD approval in the US, Hungary’s windfall tax on pharma, Presage’s collaboration with Pure Biologics and Lithuania’s biotech ambitions.   Polpharma working…

CEE Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Poland’s most promising biotech start-ups, an interview with Zentiva CEO Nick Haggar, and Takeda’s investment in an IT centre in the Slovak capital, Bratislava. Elsewhere, Pfizer has begun construction on a new…

Turkey Getinge’s president for Central and Eastern Europe, Ahmet Eke, comments on the strategic importance of the region for the Swedish company, the evolution of healthcare infrastructure in Turkey, and how Getinge competes in emerging markets against European and American medtech players.   Like many emerging markets, monetary resources are limited…

CEE The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies are looking to invest in CEE; how Polish vaccine scepticism has benefited Australia; and Hungary’s manufacturing tie-up with Chinese Sinopharm.…

Europe Jasper Kunow, MSD’s managing director for Central Eastern Europe, outlines the threat that cancer still poses to Europe, the challenges of enacting the EU’s Beating Cancer Plan across the CEE region, and how policymakers and payers can help overcome them   “In 2020, while we were all fighting against the…

Romania Mirela Iordan country manager of Pfizer Romania reveals some of her milestones, including integrating new acquisitions and setting up the first financial centre in Europe for Pfizer. She shares her insights on how the affiliate is working to maximise patients’ access to the latest innovations through patient assistance programs, early…

Romania With the 2019 acquisition of Celgene – one of the largest pharma acquisition in history – two of the sector’s most innovative oncology companies have joined forces to lead the charge against cancer. The combined entity is expected to rise in the global biopharma rankings, complete with a fresh new…

Czech Republic PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Czech Republic is available for download now.   Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s most high-performing healthcare systems, and one of the region’s leading economies, the Czech Republic’s healthcare and life sciences market is…